Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolvaptan Long-term Extension in ADPKD
NCT00841568Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Apr 2006
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tolvaptan in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Total Kidney Volume at Week 156 and Estimated Glomerular Filtration Rate at Week 156. Started Apr 2006; status: completed.
02
Drugs
tolvaptan
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT00841568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00841568.